About
Accelmed is a global group of funds investing in HealthTech companies (medical device, diagnostics and digital health) across all stages. It currently invests through two separate arms: Accelmed Partners a US-based lower market private equity HealthTech fund, focused on Buyout and Growth Investments in commercial HealthTech (>$10M LTM) companies; and, Accelmed Ventures an Israel based venture fund, focused on pre-commercialization and early revenue HealthTech Opportunities. Accelmed Partners is acquiring commercial HealthTech companies and fostering significant value creation by supporting management teams, driving innovation, providing growth capital and potentially integrating innovative add-on technologies, largely from Israel. Accelmed Partners targets equity investments of $10-50M per transaction. Accelmed Ventures aims to create successful medical device and digital health companies by using its deep expertise, extensive network and proven track record. It focuses on medical devices and digital health companies with exceptional leading teams; innovative solutions addressing unmet needs in major chronic disease areas such as neurodegenerative, oncology, metabolic and cardiovascular diseases; and companies with a proven clinical concept and/or a proven business model.
Portfolio
Investor Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is Accelmed's primary investment focus?
- Accelmed is a global group of funds investing in HealthTech companies, specifically medical devices, diagnostics, and digital health, across all stages.
- How is Accelmed structured for investments?
- Accelmed operates through two separate arms: Accelmed Partners, a US-based private equity fund for Buyout and Growth Investments in commercial HealthTech companies (>$10M LTM), and Accelmed Ventures, an Israel-based venture fund for pre-commercialization and early revenue HealthTech opportunities.
- What is the typical equity investment range for Accelmed Partners?
- Accelmed Partners targets equity investments of $10-50M per transaction.
- Which notable exits has Accelmed achieved recently?
- Accelmed has seen exits including SoniVie acquired by Boston Scientific for $400M in March 2025, and Cynerio acquired by Axonius for $180M in July 2025.
- What was a significant exit for Accelmed in 2022?
- In May 2022, Accelmed saw CartiHeal acquired by Bioventus, and in October 2022, NitiLoop was acquired by Microbot Medical.
- When did Accelmed Partners close a significant healthtech fund?
- Accelmed Partners closed a $400M healthtech fund in March 2021.
- Which company did Accelmed acquire in October 2024?
- Accelmed Partners acquired Bioventus' Advanced Rehabilitation Business in October 2024.
- What was a key IPO success for Accelmed in 2021?
- Accelmed posted a 5-fold return in the NeuroPace IPO in April 2021.
- What was Accelmed's first recorded investment according to startupim data?
- Accelmed's first recorded investment was in Medical Compression Systems in March 2009, with an amount of $2M.
- What is Accelmed's sector concentration in its portfolio?
- Accelmed's portfolio is heavily concentrated in Health Tech & Life Sciences with 18 companies, and also includes 2 companies in Cyber Security.